Original research
par
Lowenstein, Margaret et al
Date de publication
2025
Géographie
USA
Langue de la ressource
English
Texte disponible en version intégrale
Non
Open Access / OK to Reproduce
Non
Évalué par des pairs
Yes
L’objectif
To assess real-world access to buprenorphine treatment in Philadelphia and measure adoption of policies and practices that facilitate buprenorphine access.
Constatations/points à retenir
107 programs were reached with audit calls (82 % response rate). 52 % were primary care offices and 48 % were specialty addiction providers. Median time-to-appointment was 3 business days (range 0–120), and 42 % of visits were offered with a single call. Only 42 % of programs could confirm the possibility of a buprenorphine prescription at an initial visit. 48 % of programs could not provide information about requirements for counseling or behavioral health, and few could provide information about policies for patients with ongoing substance use. Specialty models were more likely than primary care programs to provide information about medication availability at the first visit but also were more likely to require counseling and abstinence.
La conception ou méthodologie de recherche
We used an audit (“secret shopper”) design to survey all programs providing longitudinal, outpatient buprenorphine in Philadelphia from 9/2022–1/2023 (n = 130).
Mots clés
Barriers and enablers
Policy/Regulatory
Substitution/OAT
Treatment/recovery